News & research updates

What's new in peptides.

Verified updates on trials, approvals and safety, checked every week against primary sources.

Latest · November 12, 2026 · 2 min read

Retatrutide in 2026: what the phase 3 trials have shown so far

Four phase 3 trials reported results between December 2025 and July 2026, and Eli Lilly plans to apply for US approval in early 2027. It is still not approved anywhere.

Read the article

November 12, 2026 · 1 min read

Philippine FDA warns against unregistered "research use" tirzepatide and retatrutide

Since September 2026 the Philippine FDA has issued a series of public health warnings against unregistered tirzepatide and retatrutide vials sold "for research use only". Here's what that means and how to check a product.

PhilippinesSafetyRegulation

November 12, 2026 · 2 min read

Tirzepatide's US label in 2026: three changes worth knowing

A new heart-risk use for people with type 2 diabetes, approval for children aged 10+ with type 2 diabetes, and the removal of a mood warning. Here's what changed, and what didn't.

TirzepatideRegulation

November 12, 2026 · 1 min read

CagriSema and elamipretide: two more peptides to watch

A weight-loss combination is awaiting a US FDA decision, and a mitochondria-targeting peptide became the first approved treatment for a rare genetic disease.

CagriSemaElamipretideRegulation

Educational summaries, not medical advice. Follow updates via RSS or our community.